Comment from International Society for CNS Clinical Trials and Methodology (ISCTM)

Summary: The International Society for CNS Clinical Trials and Methodology (ISCTM) supports the draft guidance on New Approach Methodologies (NAMs) in drug development. They suggest specific improvements, including clarifying international harmonization, establishing a public registry for accepted NAMs, and refining technical language to better incorporate real-world evidence and human-relevant data.